Agilent Technologies, Inc. (A) PT Raised to $68.00

Agilent Technologies, Inc. (NYSE:A) had its target price lifted by equities research analysts at Bank of America Corporation from $66.00 to $68.00 in a research note issued on Wednesday. The brokerage currently has an “equal weight” rating on the medical research company’s stock. Bank of America Corporation’s price target would indicate a potential upside of 11.73% from the stock’s current price.

Several other equities research analysts have also recently issued reports on the stock. Morgan Stanley restated an “overweight” rating on shares of Agilent Technologies in a report on Monday, July 10th. Jefferies Group LLC raised their target price on shares of Agilent Technologies from $59.00 to $66.00 and gave the stock a “buy” rating in a report on Tuesday, May 23rd. Deutsche Bank AG restated a “buy” rating and issued a $66.00 target price on shares of Agilent Technologies in a report on Thursday, June 22nd. BTIG Research raised their target price on shares of Agilent Technologies from $57.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, May 24th. Finally, Zacks Investment Research upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating and set a $63.00 target price on the stock in a report on Tuesday, May 16th. Three equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Agilent Technologies has a consensus rating of “Buy” and an average target price of $62.55.

Agilent Technologies (A) opened at 60.86 on Wednesday. Agilent Technologies has a 52 week low of $42.92 and a 52 week high of $62.42. The stock has a 50 day moving average price of $60.23 and a 200-day moving average price of $56.04. The stock has a market cap of $19.60 billion, a P/E ratio of 31.39 and a beta of 1.30.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Tuesday, August 15th. The medical research company reported $0.59 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.07. Agilent Technologies had a net margin of 14.36% and a return on equity of 17.25%. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter last year, the firm earned $0.49 earnings per share. The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. On average, equities analysts anticipate that Agilent Technologies will post $2.31 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Agilent Technologies, Inc. (A) PT Raised to $68.00” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://sportsperspectives.com/2017/08/18/agilent-technologies-inc-a-pt-raised-to-68-00.html.

In other news, insider Patrick Kaltenbach sold 2,074 shares of the firm’s stock in a transaction on Wednesday, May 31st. The shares were sold at an average price of $60.43, for a total transaction of $125,331.82. Following the sale, the insider now directly owns 42,212 shares in the company, valued at approximately $2,550,871.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael R. Mcmullen sold 50,000 shares of the firm’s stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $59.86, for a total transaction of $2,993,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 125,615 shares of company stock worth $7,543,943 in the last quarter.

Several hedge funds have recently made changes to their positions in the stock. Balentine LLC increased its stake in shares of Agilent Technologies by 2.9% in the second quarter. Balentine LLC now owns 1,794 shares of the medical research company’s stock valued at $106,000 after buying an additional 50 shares during the last quarter. Sun Life Financial INC increased its stake in shares of Agilent Technologies by 26,144.4% in the second quarter. Sun Life Financial INC now owns 2,362 shares of the medical research company’s stock valued at $140,000 after buying an additional 2,353 shares during the last quarter. Trust Co. of Vermont increased its stake in shares of Agilent Technologies by 8.1% in the first quarter. Trust Co. of Vermont now owns 2,743 shares of the medical research company’s stock valued at $145,000 after buying an additional 205 shares during the last quarter. Acrospire Investment Management LLC increased its stake in shares of Agilent Technologies by 92.3% in the second quarter. Acrospire Investment Management LLC now owns 2,500 shares of the medical research company’s stock valued at $148,000 after buying an additional 1,200 shares during the last quarter. Finally, Parallel Advisors LLC increased its stake in shares of Agilent Technologies by 5.3% in the second quarter. Parallel Advisors LLC now owns 2,623 shares of the medical research company’s stock valued at $157,000 after buying an additional 131 shares during the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply